News

Public · Published

BWXT Q3 deep dive: nuclear growth pipeline advances despite revenue miss

BWXT reported third-quarter 2026 revenue of $953 million, up 10% year over year but below analysts' $973.1 million estimate. Adjusted earnings were $1.26 per share, above estimates, while management reaffirmed full-year adjusted earnings guidance of $4.74 per share at the midpoint and reported an $8.56 billion backlog.

Published:

Updated:

What happened

BWXT reported third-quarter 2026 revenue of $953 million, up 10% year over year but below analysts’ $973.1 million estimate. Adjusted earnings were $1.26 per share, above estimates, while management reaffirmed full-year adjusted earnings guidance of $4.74 per share at the midpoint and reported an $8.56 billion backlog.

Confirmed

Global impact / market context

Revenue below expectations shows that sales growth did not fully meet analysts’ near-term forecasts. Higher adjusted earnings and a larger backlog offer counterpoints: if the backlog converts into completed work and sales, it could support future revenue, while reaffirmed earnings guidance signals no change to management’s stated target.

Analyst inference

The results present a mixed picture for BWXT: revenue missed expectations, while adjusted earnings and full-year EBITDA guidance exceeded analyst estimates. The article reports a negative market reaction, but does not give its size; the backlog’s value depends on delivery timing and conversion into revenue.

Confirmed

What to watch

  1. Watch subsequent revenue reports for whether the 10% year-over-year growth continues and whether sales move closer to analysts’ expectations after this quarter’s shortfall. Analyst inference
  2. Track whether management maintains its $4.74 adjusted earnings-per-share midpoint and $667 million full-year EBITDA midpoint in later updates. Confirmed
  3. Follow backlog changes and its conversion into reported sales; a rising backlog could support future revenue only if BWXT delivers the contracted work. Analyst inference

Evidence